HIV/AIDS-Equivalent Immune Collapse (AEIC)
Document Code: SCF-AEIC-TSB-0001
Framework Integration:
SCF Gene-Class Atlas | AEIC Gene Library | AEIC Target Priority Matrix | AEIC API Discovery Map | SCF Synergistic Compatibility Framework | FDA Translational Development Workflow
Purpose:
Define a complete therapeutic architecture that restores immune function in AEIC by targeting the five SCF fault domains through a multi-target synergistic therapeutic stack.
1. Therapeutic Stack Strategy
The SCF AEIC stack follows the PCR Braid Model:
Layer | Objective |
Preventative | Prevent viral entry and immune collapse |
Curative | Suppress viral replication and restore immune circuits |
Restorative | Repair immune architecture and metabolic resilience |
The stack targets five core SCF fault domains:
SCF Fault Domain | AEIC Pathology |
Viral Entry Control | host infection initiation |
Immune Circuit Collapse | CD4 depletion and exhaustion |
Metabolic Failure | mitochondrial dysfunction |
Antiviral Defense Failure | viral replication persistence |
Xenobiotic Amplification | immune suppression signaling |
2. SCF Fibonacci Therapeutic Stack Architecture
The SCF design uses a Fibonacci synergy stack to ensure balanced therapeutic coverage.
Stack Position | Component Class | Target Axis |
1 | Viral Entry Inhibitor | CCR5/CXCR4 |
1 | Antiviral Restriction Activator | APOBEC3G / IFITM3 |
2 | Immune Checkpoint Modulator | PD-1 / CTLA-4 |
3 | Metabolic Activator | AMPK / mTOR |
5 | Redox Stabilizer | NRF2 / antioxidant systems |
This design improves:
- resistance prevention
- immune restoration
- metabolic resilience
3. Core Therapeutic Components
3.1 Viral Entry Blockade Module
Component | Mechanism | Target |
CCR5 antagonist | receptor blockade | CCR5 |
CXCR4 inhibitor | viral entry disruption | CXCR4 |
Therapeutic Role
Prevents host cell infection and viral spread.
SCF Role
Target-Specific Modulator.
3.2 Antiviral Restriction Module
Component | Mechanism |
APOBEC activation | viral genome editing |
IFITM activation | viral membrane restriction |
TRIM5 stimulation | capsid destabilization |
Therapeutic Role
Suppress viral replication.
SCF Role
Resistance-Prevention Engine.
3.3 Immune Circuit Restoration Module
Component | Mechanism |
PD-1 inhibitor | reverse T-cell exhaustion |
IL-7 therapy | lymphocyte survival |
IL-2 modulation | T-cell expansion |
Therapeutic Role
Restore immune response.
SCF Role
Immune Circuit Reconstructor.
3.4 Metabolic Restoration Module
Component | Mechanism |
AMPK activator | mitochondrial energy restoration |
mTOR modulation | immune metabolic balance |
SIRT1 activation | mitochondrial stabilization |
Therapeutic Role
Restore immune cell energy.
SCF Role
Metabolic Regulator.
3.5 Redox Stabilization Module
Component | Mechanism |
NRF2 activation | antioxidant defense |
glutathione restoration | oxidative stress reduction |
mitochondrial ROS control | cellular protection |
Therapeutic Role
Prevent immune cell oxidative damage.
SCF Role
Safety Harmonizer.
4. Therapeutic Stack Integration Matrix
Module | Target Genes | Biological Outcome |
Entry Blockade | CCR5, CXCR4 | infection prevention |
Antiviral Restriction | APOBEC3G, IFITM3 | viral replication suppression |
Immune Restoration | PDCD1, IL7, IL2 | T-cell recovery |
Metabolic Recovery | PRKAA1, MTOR | immune energy restoration |
Redox Stabilization | NRF2, GPX1 | oxidative protection |
5. Pharmacokinetic Delivery Architecture
Delivery Platform | Function |
lipid nanoparticles | lymphatic targeting |
polymeric nanoparticles | sustained release |
prodrug activation | metabolic efficiency |
implantable depots | long-term viral suppression |
The design prioritizes lymphatic tissue delivery, where immune collapse is concentrated.
6. Synergistic Compatibility Evaluation
The stack is evaluated using SCF synergy metrics.
Metric | Function |
TSSM | resistance-prevention capacity |
HSV-F² | metabolic compatibility |
SV-EQ | target specificity |
MGIS | molecular geometry compatibility |
SPCI | safety compatibility |
Expected synergy score: > 0.82 composite compatibility threshold.
7. Resistance Prevention Architecture
The SCF stack prevents viral escape by targeting multiple viral lifecycle stages.
Viral Stage | Intervention |
Entry | CCR5 / CXCR4 blockade |
Reverse transcription | APOBEC activation |
Viral budding | tetherin activation |
Immune evasion | PD-1 inhibition |
Multi-axis targeting dramatically increases the viral resistance barrier.
8. Preclinical Development Framework
Required Experimental Modules
Module | Function |
viral replication assays | antiviral activity |
immune exhaustion profiling | T-cell restoration |
cytokine network analysis | immune signaling |
mitochondrial respiration testing | metabolic recovery |
oxidative stress assays | redox stabilization |
9. Clinical Development Strategy
Phase I
Safety and pharmacokinetics.
Phase II
Immune restoration evaluation.
Phase III
Long-term viral suppression and immune recovery.
10. Primary Clinical Endpoints
Endpoint | Measurement |
immune restoration | CD4/CD8 ratio |
viral suppression | plasma viral load |
metabolic recovery | ATP:cAMP ratio |
inflammatory balance | cytokine panels |
11. Integration with Project RHENOVA
The AEIC Therapeutic Stack forms the immune reconstruction arm of the RHENOVA therapeutic platform.
Applications include:
- chronic viral infection treatment
- immune collapse syndromes
- xenobiotic-viral convergence disorders
12. Strategic Next Research Pathways
Next SCF development documents include:
- SCF AEIC Pharmacokinetic Modeling Report
- SCF AEIC Preclinical Experimental Program
- SCF AEIC IND Preparation Dossier
- SCF AEIC Clinical Trial Protocol
These convert the therapeutic stack into regulatory-ready drug development pipelines.
13. SCF Master Registry Index
SCF-AEIC-TSB-0001
SCF-AEIC-ADM-0001
SCF-AEIC-TPM-0001
SCF-AEIC-GL-0001
SCF-GCA-AEIC-0001
SCF-SEF-MD-0001
SCF-API-DP-0001
SCF-PP-UVT-0001
SCF-CRD-WORKFLOW-0001
SCF-VECTIS-409-PIPELINE-0001